Aspect Biosystems
Aspect Biosystems is a Canadian biotechnology company focused on creating bioprinted tissue therapeutics to transform disease treatment. Their innovative platform integrates AI-powered bioprinting, computational design, therapeutic cells, and biomaterials to develop allogeneic tissue therapeutics for regenerative medicine, metabolic, and endocrine diseases. They collaborate globally with industry and academic partners to advance research and develop impactful therapies.
Industries
Nr. of Employees
medium (51-250)
Aspect Biosystems
2131 Manitoba Street, Vancouver, BC, Canada V5Y 0N7
Patents
System for additive manufacturing of three-dimensional structures and method for same
US-11738501-B2
View DetailsSystem for additive manufacturing of three-dimensional structures and method for same
US-11046930-B2
View Details
System for additive manufacturing of three-dimensional structures and method for same
US-11738501-B2
View DetailsSystem for additive manufacturing of three-dimensional structures and method for same
US-11046930-B2
View DetailsProducts
Full‑stack tissue therapeutic platform
Integrated platform combining microfluidic 3D bioprinting, computational design, therapeutic cells, and biomaterials to develop implantable allogeneic tissue therapeutics.
Microfluidic bioprinter instrument
Laboratory-scale microfluidic bioprinting instrument designed to fabricate 3D tissue constructs for research and translational applications.
Pipeline of implantable bioprinted tissue therapeutics
In-house therapeutic programs focused on implantable bioprinted tissues targeting metabolic and endocrine diseases (including pancreatic, liver, and related indications).
Full‑stack tissue therapeutic platform
Integrated platform combining microfluidic 3D bioprinting, computational design, therapeutic cells, and biomaterials to develop implantable allogeneic tissue therapeutics.
Microfluidic bioprinter instrument
Laboratory-scale microfluidic bioprinting instrument designed to fabricate 3D tissue constructs for research and translational applications.
Pipeline of implantable bioprinted tissue therapeutics
In-house therapeutic programs focused on implantable bioprinted tissues targeting metabolic and endocrine diseases (including pancreatic, liver, and related indications).
Services
Co-development arrangements with academic and industry partners to develop tissue models and implantable tissue therapeutics; includes technology transfer and joint development.
Provision of access to the company's tissue fabrication platform and associated protocols to enable external research and development projects.
Co-development arrangements with academic and industry partners to develop tissue models and implantable tissue therapeutics; includes technology transfer and joint development.
Provision of access to the company's tissue fabrication platform and associated protocols to enable external research and development projects.
Expertise Areas
- 3D bioprinting and biofabrication
- Microfluidics
- Biomaterials and hydrogel engineering
- Tissue engineering and regenerative medicine
Key Technologies
- Microfluidic 3D bioprinting
- Computational tissue design
- AI-driven design workflows
- Bio-ink and hydrogel formulation
News & Updates
Aspect Biosystems announced a $20 million Series A financing round led by Radical Ventures, with proceeds to advance tissue therapeutic programs, expand technology capabilities, and grow its team.
A joint development program with JSR Corporation to combine bioprinting with advanced materials for implantable vascularized tissues for kidney regeneration and other applications.
Andrew Booth, with extensive experience in scaling life sciences companies, joins the board to support pipeline advancement and company growth.
A multi-year project supported by government investment to develop clinical biomanufacturing capabilities and pipeline of bioprinted tissue therapeutics for metabolic and endocrine diseases.
Tamer Mohamed, co-founder and former CTO, appointed as President & CEO to lead commercialization and growth.
A successful funding round supported by global investors to accelerate technology development and commercialization.
Aspect Biosystems announced a $20 million Series A financing round led by Radical Ventures, with proceeds to advance tissue therapeutic programs, expand technology capabilities, and grow its team.
A joint development program with JSR Corporation to combine bioprinting with advanced materials for implantable vascularized tissues for kidney regeneration and other applications.
Andrew Booth, with extensive experience in scaling life sciences companies, joins the board to support pipeline advancement and company growth.
A multi-year project supported by government investment to develop clinical biomanufacturing capabilities and pipeline of bioprinted tissue therapeutics for metabolic and endocrine diseases.
Tamer Mohamed, co-founder and former CTO, appointed as President & CEO to lead commercialization and growth.
A successful funding round supported by global investors to accelerate technology development and commercialization.